The Fe(ii) complex of the L ligand (L = 6-(3,5-diamino-2,4,6-triazinyl)-2,2'-bipyridine) has been used as a templating cation for the growth of oxalate-based networks. The magnetic characterization of the [Fe(L)](ClO)·CHCN (1) precursor in the solid state has been performed for the first time showing that the low-spin (LS) state is predominating from 2 to 400 K with 10% of Fe(ii), which undergoes a gradual and irreversible spin-crossover above 350 K. 1 presents the LIESST effect with a photo-conversion close to 25% and a T(LIESST) of 49 K. During the preparation of 1, a secondary product of the formula [Fe(L)(CHCN)(HO)](ClO)·CHCN (2) has been obtained. The magnetic characterization of 2 shows that it contains high-spin (HS) Fe(ii). 1 has afforded two novel oxalate-based compounds, the 2D compound of the formula [Fe(L)][MnCr(ox)]·(CHNO)·(CHOH)·(HO) (3) and the 3D compound of the formula [Fe(L)][MnCr(ox)]·(CHCN) (4), which have been obtained by changing the synthetic conditions. The magnetic properties show that in 3 the inserted Fe(ii) cation remains in the LS state from 2 to 340 K and presents a partial and irreversible spin-crossover of ∼20% at higher temperatures. In 4, most of the Fe(ii) complexes remain in the LS state from 2 to 230 K and present a partial and irreversible spin-crossover of ∼50% from 230 to 400 K. 3 and 4 do not present the LIESST effect.
The 1:2 and 1:1 Co(II) complexes of L ligand (L = 6-(3,5-Diamino-2,4,6-triazinyl)2,2’-bipyridine) with formula [CoII(L)2](ClO4)2·0.5MeCN·Et2O·0.25H2O (1) and [CoII(L)(CH3CN)2(H2O)](ClO4)2·MeCN (2) have been prepared. The structural and magnetic characterization of the two...
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.